Brief: Celltrion USA Receives U.S. FDA Approval For Its Oncology Biosimilar Vegzelma For Treatment Of Six Types Of Cancer
Sept 28 (Reuters) - Celltrion Healthcare Co Ltd
091990.KQ :
* CELLTRION USA RECEIVES U.S. FDA APPROVAL FOR ITS ONCOLOGY
BIOSIMILAR VEGZELMA® (BEVACIZUMAB-ADCD) FOR THE TREATMENT OF SIX
TYPES OF CANCER
* CELLTRION USA- APPROVAL BASED ON TOTALITY OF EVIDENCE WITH
NO
CLINICALLY MEANINGFUL DIFFERENCES IN EFFICACY OR SAFETY WITH
REFERENCE PRODUCT AVASTIN
Source text for Eikon: ID:nBwbtVvWka
Further company coverage: 091990.KQ
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Celltrion Healthcare Co
See all newsBrief: Celltrion USA says Ventegra Will Place FDA-Approved Biosimilar To Avastin , Vegzelma On Its Commercial Formulary As A Preferred Brand
Brief: Celltrion Healthcare To Acquire 92.7 Billion Won Worth Of Own Shares
Brief: Celltrion Healthcare Q3 Operating Profit 50.5 Billion Won, Down 30.4% From Year Earlier
Brief: Celltrion Usa- Announces Distribution And Incorporation Of Yuflyma (Adalimumab-Aaty) To Carepartners Specialty Pharmacy Cost Savings Programs
Brief: Celltrion Healthcare's Merger With Celltrion Approved In Shareholder Meeting -Yonhap